Nexell to be sole marketer of cell selection system in US
This article was originally published in Clinica
Executive Summary
Nexell Therapeutics' Isolex magnetic cell selection system has been cleared for marketing in the US - when launched, it will be the only such system commercially available in the US. The semi-automated Isolex and the fully-automated Isolex 300i will be sold for the selection of haematopoietic stem cells and the removal of tumour cells from autologous peripheral blood as part of cancer treatment.